Bioengineering Program, School of Engineering, The University of Kansas, 1530 W 15th Street, Lawrence, Kansas, 66045, USA.
Amgen, Thousand Oaks, California, USA.
AAPS PharmSciTech. 2023 Apr 20;24(5):104. doi: 10.1208/s12249-023-02561-4.
Polysorbates (PS) are nonionic surfactants that are commonly included in protein formulations to mitigate the formation of interfacial stress-induced protein particles and thus increase their long-term storage stability. Nonetheless, factors that dictate the efficiency of different polysorbates in mitigating protein particle formation, especially during the application of interfacial stresses, are often ill defined. Here, we used a Langmuir trough to determine the surface activity of two IgG1 monoclonal antibodies formulated with two different polysorbates (PS20 and PS80) when subjected to interfacial dilatational stress. Interfacial properties of these formulations were then correlated with characterization of subvisible protein particles measured by micro-flow imaging (MFI). Both mAbs, when formulated in PS20, demonstrate faster adsorption kinetics and higher surface activity compared to PS80 or surfactant-free formulations. Compression/expansion results suggest that when exposed to interfacial dilatational stresses, both mAb/PS20 formulations display interfacial properties of PS20 alone. In contrast, interfacial properties of both mAb/PS80 formulations suggest mAbs and PS80 are co-adsorbed to the air-water interface. Further, MFI analysis of the interface and the bulk solution confirms that PS20 is more effective than PS80 at mitigating the formation of larger particles in the bulk solution in both mAbs. Concomitantly, the efficiency of PS to prevent interface-induced protein particle formation also depended on the protein's inherent tendency to aggregate at a surfactant-free interface. Together, the studies presented here highlight the importance of determining the interfacial properties of mAbs, surfactants, and their combinations to make informed formulation decisions about the choice of surfactant.
聚山梨酯(PS)是非离子表面活性剂,通常包含在蛋白质配方中,以减轻界面应力诱导的蛋白质颗粒的形成,从而提高其长期储存稳定性。然而,决定不同聚山梨酯在减轻蛋白质颗粒形成效率的因素,尤其是在施加界面应力时,往往定义不明确。在这里,我们使用 Langmuir 槽来确定两种 IgG1 单克隆抗体在受到界面扩张应力时用两种不同的聚山梨酯(PS20 和 PS80)配制时的表面活性。然后将这些配方的界面性质与通过微流成像(MFI)测量的亚可见蛋白质颗粒的特征相关联。与 PS80 或无表面活性剂配方相比,当用 PS20 配制时,这两种 mAb 都表现出更快的吸附动力学和更高的表面活性。压缩/扩展结果表明,当暴露于界面扩张应力时,两种 mAb/PS20 制剂均显示出 PS20 单独的界面性质。相比之下,两种 mAb/PS80 制剂的界面性质表明 mAb 和 PS80 共同被吸附到气-液界面上。此外,界面和本体溶液的 MFI 分析证实,PS20 在两种 mAb 中都比 PS80 更有效地减轻本体溶液中较大颗粒的形成。同时,PS 防止界面诱导的蛋白质颗粒形成的效率也取决于蛋白质在无表面活性剂界面上固有聚集的倾向。综上所述,本研究强调了确定 mAb、表面活性剂及其组合的界面性质的重要性,以便就表面活性剂的选择做出明智的配方决策。